<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:07:34 -0700</creation_date>
  <update_date>2013-01-15 20:07:34 -0700</update_date>
  <accession>HMDBP08199</accession>
  <secondary_accessions>
    <accession>13910</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>GABA(A) receptor subunit alpha-2</synonym>
  </synonyms>
  <gene_name>GABRA2</gene_name>
  <general_function>Involved in ion transport</general_function>
  <specific_function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00492</accession>
      <name>Chlorine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00112</accession>
      <name>Gamma-Aminobutyric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14332</accession>
      <name>Lorazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14335</accession>
      <name>Ethchlorvynol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14376</accession>
      <name>Temazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14382</accession>
      <name>Butabarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14386</accession>
      <name>Butalbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14451</accession>
      <name>Talbutal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14457</accession>
      <name>Pentobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14493</accession>
      <name>Clobazam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14515</accession>
      <name>Meprobamate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13943</accession>
      <name>Alpha-hydroxyalprazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14562</accession>
      <name>Secobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14606</accession>
      <name>Metharbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14618</accession>
      <name>Chlordiazepoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14686</accession>
      <name>Adinazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14737</accession>
      <name>Thiopental</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14766</accession>
      <name>Clorazepate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14821</accession>
      <name>Midazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14828</accession>
      <name>Flurazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14932</accession>
      <name>Primidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14939</accession>
      <name>Halazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14980</accession>
      <name>Oxazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14987</accession>
      <name>Methylphenobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15034</accession>
      <name>Triazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15201</accession>
      <name>Clonazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15329</accession>
      <name>Zopiclone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15336</accession>
      <name>Flumazenil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15346</accession>
      <name>Estazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15436</accession>
      <name>Quinidine barbiturate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15440</accession>
      <name>Amobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15441</accession>
      <name>Aprobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15442</accession>
      <name>Butethal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15443</accession>
      <name>Heptabarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13940</accession>
      <name>3'-Hydroxyhexobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15510</accession>
      <name>Flunitrazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15511</accession>
      <name>Bromazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15512</accession>
      <name>Clotiazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15513</accession>
      <name>Fludiazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15527</accession>
      <name>Prazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15528</accession>
      <name>Quazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15533</accession>
      <name>Cinolazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15534</accession>
      <name>Nitrazepam</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>extracellular ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>substrate-specific transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gaba receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gaba-a receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>gamma-aminobutyric acid signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>anion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>inorganic anion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>chloride transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>postsynaptic membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell junction</subcellular_location>
    <subcellular_location>synapse</subcellular_location>
    <subcellular_location>postsynaptic cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:4</chromosome_location>
    <locus>4p12</locus>
    <gene_sequence>&gt;1356 bp
ATGAAGACAAAATTGAACATCTACAACATGCAGTTCCTGCTTTTTGTTTTCTTGGTGTGG
GACCCTGCCAGGTTGGTGCTGGCTAACATCCAAGAAGATGAGGCTAAAAATAACATTACC
ATCTTTACGAGAATTCTTGACAGACTTCTGGATGGTTACGATAATCGGCTTAGACCAGGA
CTGGGAGACAGTATTACTGAAGTCTTCACTAACATCTACGTGACCAGTTTTGGCCCTGTC
TCAGATACAGATATGGAATATACAATTGATGTTTTCTTTCGACAAAAATGGAAAGATGAA
CGTTTAAAATTTAAAGGTCCTATGAATATCCTTCGACTAAACAATTTAATGGCTAGCAAA
ATCTGGACTCCAGATACCTTTTTTCACAATGGGAAAAAATCAGTAGCTCATAATATGACA
ATGCCAAATAAGTTGCTTCGAATTCAGGATGATGGGACTCTGCTGTATACCATGAGGCTT
ACAGTTCAAGCTGAATGCCCAATGCACTTGGAGGATTTCCCAATGGATGCTCATTCATGT
CCTCTGAAATTTGGCAGCTATGCATATACAACTTCAGAGGTCACTTATATTTGGACTTAC
AATGCATCTGATTCAGTACAGGTTGCTCCTGATGGCTCTAGGTTAAATCAATATGACCTG
CTGGGCCAATCAATCGGAAAGGAGACAATTAAATCCAGTACAGGTGAATATACTGTAATG
ACAGCTCATTTCCACCTGAAAAGAAAAATTGGGTATTTTGTGATTCAAACCTATCTGCCT
TGCATCATGACTGTCATTCTCTCCCAAGTTTCATTCTGGCTTAACAGAGAATCTGTGCCT
GCAAGAACTGTGTTTGGAGTAACAACTGTCCTAACAATGACAACTCTAAGCATCAGTGCT
CGGAATTCTCTCCCCAAAGTGGCTTATGCAACTGCCATGGACTGGTTTATTGCTGTTTGT
TATGCATTTGTGTTCTCTGCCCTAATTGAATTTGCAACTGTTAATTACTTCACCAAAAGA
GGATGGGCTTGGGATGGGAAGAGTGTAGTAAATGACAAGAAAAAAGAAAAGGCTTCCGTT
ATGATACAGAACAACGCTTATGCAGTGGCTGTTGCCAATTATGCCCCGAATCTTTCAAAA
GATCCAGTTCTCTCCACCATCTCCAAGAGTGCAACCACGCCAGAACCCAACAAGAAGCCA
GAAAACAAGCCAGCTGAAGCAAAGAAAACTTTCAACAGTGTTAGCAAAATTGACAGAATG
TCCAGAATAGTTTTTCCAGTTTTGTTTGGTACCTTTAATTTAGTTTACTGGGCTACATAT
TTAAACAGAGAACCTGTATTAGGGGTCAGTCCTTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>451</residue_number>
    <molecular_weight>51325.9</molecular_weight>
    <theoretical_pi>9.5</theoretical_pi>
    <pfams>
      <pfam>
        <name>Neur_chan_LBD</name>
        <pfam_id>PF02931</pfam_id>
      </pfam>
      <pfam>
        <name>Neur_chan_memb</name>
        <pfam_id>PF02932</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>252-273</region>
      <region>279-300</region>
      <region>313-334</region>
      <region>420-441</region>
    </transmembrane_regions>
    <signal_regions>
      <region>1-28</region>
    </signal_regions>
    <protein_sequence>&gt;Gamma-aminobutyric acid receptor subunit alpha-2
MKTKLNIYNMQFLLFVFLVWDPARLVLANIQEDEAKNNITIFTRILDRLLDGYDNRLRPG
LGDSITEVFTNIYVTSFGPVSDTDMEYTIDVFFRQKWKDERLKFKGPMNILRLNNLMASK
IWTPDTFFHNGKKSVAHNMTMPNKLLRIQDDGTLLYTMRLTVQAECPMHLEDFPMDAHSC
PLKFGSYAYTTSEVTYIWTYNASDSVQVAPDGSRLNQYDLLGQSIGKETIKSSTGEYTVM
TAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA
RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKSVVNDKKKEKASV
MIQNNAYAVAVANYAPNLSKDPVLSTISKSATTPEPNKKPENKPAEAKKTFNSVSKIDRM
SRIVFPVLFGTFNLVYWATYLNREPVLGVSP</protein_sequence>
  </protein_properties>
  <genbank_protein_id>167000751</genbank_protein_id>
  <uniprot_id>P47869</uniprot_id>
  <uniprot_name>GBRA2_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>NM_000807.2</genbank_gene_id>
  <genecard_id>GABRA2</genecard_id>
  <geneatlas_id>GABRA2</geneatlas_id>
  <hgnc_id>HGNC:4076</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Hadingham KL, Wingrove P, Le Bourdelles B, Palmer KJ, Ragan CI, Whiting PJ: Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acidA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acidA receptors. Mol Pharmacol. 1993 Jun;43(6):970-5.</reference_text>
      <pubmed_id>8391122</pubmed_id>
    </reference>
    <reference>
      <reference_text>Edenberg HJ, Dick DM, Xuei X, Tian H, Almasy L, Bauer LO, Crowe RR, Goate A, Hesselbrock V, Jones K, Kwon J, Li TK, Nurnberger JI Jr, O'Connor SJ, Reich T, Rice J, Schuckit MA, Porjesz B, Foroud T, Begleiter H: Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet. 2004 Apr;74(4):705-14. Epub 2004 Mar 12.</reference_text>
      <pubmed_id>15024690</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethchlorvynol</name>
        <accession>HMDB14335</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethchlorvynol</name>
        <accession>HMDB14335</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butabarbital</name>
        <accession>HMDB14382</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butabarbital</name>
        <accession>HMDB14382</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butalbital</name>
        <accession>HMDB14386</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butalbital</name>
        <accession>HMDB14386</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Talbutal</name>
        <accession>HMDB14451</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Talbutal</name>
        <accession>HMDB14451</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentobarbital</name>
        <accession>HMDB14457</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentobarbital</name>
        <accession>HMDB14457</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meprobamate</name>
        <accession>HMDB14515</accession>
      </metabolite>
      <reference>
        <reference_text>Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91.</reference_text>
        <pubmed_id>9067327</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meprobamate</name>
        <accession>HMDB14515</accession>
      </metabolite>
      <reference>
        <reference_text>Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. Epub 2009 Feb 24.</reference_text>
        <pubmed_id>19244096</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alpha-hydroxyalprazolam</name>
        <accession>HMDB13943</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Secobarbital</name>
        <accession>HMDB14562</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Secobarbital</name>
        <accession>HMDB14562</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metharbital</name>
        <accession>HMDB14606</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metharbital</name>
        <accession>HMDB14606</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adinazolam</name>
        <accession>HMDB14686</accession>
      </metabolite>
      <reference>
        <reference_text>Lahti RA, Sethy VH, Barsuhn C, Hester JB: Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology. 1983 Nov;22(11):1277-82.</reference_text>
        <pubmed_id>6320036</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adinazolam</name>
        <accession>HMDB14686</accession>
      </metabolite>
      <reference>
        <reference_text>Sethy VH, Collins RJ, Daniels EG: Determination of biological activity of adinazolam and its metabolites.  J Pharm Pharmacol. 1984 Aug;36(8):546-8.</reference_text>
        <pubmed_id>6148400</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thiopental</name>
        <accession>HMDB14737</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thiopental</name>
        <accession>HMDB14737</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primidone</name>
        <accession>HMDB14932</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primidone</name>
        <accession>HMDB14932</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Halazepam</name>
        <accession>HMDB14939</accession>
      </metabolite>
      <reference>
        <reference_text>Iorio LC, Barnett A, Billard W: Selective affinity of 1-N-trifluoroethyl benzodiazepines for cerebellar type 1 receptor sites. Life Sci. 1984 Jul 2;35(1):105-13.</reference_text>
        <pubmed_id>6738302</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Halazepam</name>
        <accession>HMDB14939</accession>
      </metabolite>
      <reference>
        <reference_text>Wamsley JK, Golden JS, Yamamura HI, Barnett A: Autoradiographic demonstration of the selectivity of two 1-N-trifluoroethyl benzodiazepines for the BZD-1 receptors in the rat brain. Pharmacol Biochem Behav. 1985 Dec;23(6):973-8.</reference_text>
        <pubmed_id>2867566</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. Epub 2010 Dec 31.</reference_text>
        <pubmed_id>21194017</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clonazepam</name>
        <accession>HMDB15201</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clonazepam</name>
        <accession>HMDB15201</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zopiclone</name>
        <accession>HMDB15329</accession>
      </metabolite>
      <reference>
        <reference_text>Nutt DJ, Stahl SM: Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010 Nov;24(11):1601-12. Epub 2009 Nov 26.</reference_text>
        <pubmed_id>19942638</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zopiclone</name>
        <accession>HMDB15329</accession>
      </metabolite>
      <reference>
        <reference_text>Hanson SM, Morlock EV, Satyshur KA, Czajkowski C: Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different. J Med Chem. 2008 Nov 27;51(22):7243-52.</reference_text>
        <pubmed_id>18973287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zopiclone</name>
        <accession>HMDB15329</accession>
      </metabolite>
      <reference>
        <reference_text>Ramerstorfer J, Furtmuller R, Vogel E, Huck S, Sieghart W: The point mutation gamma 2F77I changes the potency and efficacy of benzodiazepine site ligands in different GABAA receptor subtypes. Eur J Pharmacol. 2010 Jun 25;636(1-3):18-27. Epub 2010 Mar 19.</reference_text>
        <pubmed_id>20303942</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flumazenil</name>
        <accession>HMDB15336</accession>
      </metabolite>
      <reference>
        <reference_text>Clement Y, Le Guisquet AM, Venault P, Chapouthier G, Belzung C: Pharmacological alterations of anxious behaviour in mice depending on both strain and the behavioural situation. PLoS One. 2009 Nov 11;4(11):e7745.</reference_text>
        <pubmed_id>19907641</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flumazenil</name>
        <accession>HMDB15336</accession>
      </metabolite>
      <reference>
        <reference_text>Hosaka K, Jackson D, Pickrell JE, Heima M, Milgrom P: Flumazenil reversal of sublingual triazolam: a randomized controlled clinical trial. J Am Dent Assoc. 2009 May;140(5):559-66.</reference_text>
        <pubmed_id>19411525</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flumazenil</name>
        <accession>HMDB15336</accession>
      </metabolite>
      <reference>
        <reference_text>Ngo AS, Anthony CR, Samuel M, Wong E, Ponampalam R: Should a benzodiazepine antagonist be used in unconscious patients presenting to the emergency department? Resuscitation. 2007 Jul;74(1):27-37. Epub 2007 Feb 15.</reference_text>
        <pubmed_id>17306436</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flumazenil</name>
        <accession>HMDB15336</accession>
      </metabolite>
      <reference>
        <reference_text>Olkkola KT, Ahonen J: Midazolam and other benzodiazepines.  Handb Exp Pharmacol. 2008;(182):335-60.</reference_text>
        <pubmed_id>18175099</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flumazenil</name>
        <accession>HMDB15336</accession>
      </metabolite>
      <reference>
        <reference_text>Maeda S, Miyawaki T, Higuchi H, Shimada M: Effect of flumazenil on disturbance of equilibrium function induced by midazolam.  Anesth Prog. 2008 Fall;55(3):73-7.</reference_text>
        <pubmed_id>18788841</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flumazenil</name>
        <accession>HMDB15336</accession>
      </metabolite>
      <reference>
        <reference_text>Raffa RB, Cavallo F, Capasso A: Flumazenil-sensitive dose-related physical dependence in planarians produced by two benzodiazepine and one non-benzodiazepine benzodiazepine-receptor agonists. Eur J Pharmacol. 2007 Jun 14;564(1-3):88-93. Epub 2007 Feb 16.</reference_text>
        <pubmed_id>17368613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estazolam</name>
        <accession>HMDB15346</accession>
      </metabolite>
      <reference>
        <reference_text>Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain.  Eur J Pharmacol. 1978 Apr 1;48(3):263-70.</reference_text>
        <pubmed_id>639854</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estazolam</name>
        <accession>HMDB15346</accession>
      </metabolite>
      <reference>
        <reference_text>Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601.</reference_text>
        <pubmed_id>2889803</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Stobbs SH, Ohran AJ, Lassen MB, Allison DW, Brown JE, Steffensen SC: Ethanol suppression of ventral tegmental area GABA neuron electrical transmission involves N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 2004 Oct;311(1):282-9. Epub 2004 May 28.</reference_text>
        <pubmed_id>15169831</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amobarbital</name>
        <accession>HMDB15440</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amobarbital</name>
        <accession>HMDB15440</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprobarbital</name>
        <accession>HMDB15441</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprobarbital</name>
        <accession>HMDB15441</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butethal</name>
        <accession>HMDB15442</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butethal</name>
        <accession>HMDB15442</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Heptabarbital</name>
        <accession>HMDB15443</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Heptabarbital</name>
        <accession>HMDB15443</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines].  Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72.</reference_text>
        <pubmed_id>2570451</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Oblak AL, Gibbs TT, Blatt GJ: Reduced GABAA receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism. Brain Res. 2011 Mar 22;1380:218-28. Epub 2010 Sep 19.</reference_text>
        <pubmed_id>20858465</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>You H, Kozuska JL, Paulsen IM, Dunn SM: Benzodiazepine modulation of the rat GABAA receptor alpha4beta3gamma2L subtype expressed in Xenopus oocytes. Neuropharmacology. 2010 Nov;59(6):527-33. Epub 2010 Jul 16.</reference_text>
        <pubmed_id>20638393</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Skilbeck KJ, O'Reilly JN, Johnston GA, Hinton T: Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):492-8. Epub 2007 Oct       10.</reference_text>
        <pubmed_id>17976880</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromazepam</name>
        <accession>HMDB15511</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clotiazepam</name>
        <accession>HMDB15512</accession>
      </metabolite>
      <reference>
        <reference_text>Mandrioli R, Mercolini L, Raggi MA: Benzodiazepine metabolism: an analytical perspective.  Curr Drug Metab. 2008 Oct;9(8):827-44.</reference_text>
        <pubmed_id>18855614</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fludiazepam</name>
        <accession>HMDB15513</accession>
      </metabolite>
      <reference>
        <reference_text>Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9.</reference_text>
        <pubmed_id>2857046</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazepam</name>
        <accession>HMDB15527</accession>
      </metabolite>
      <reference>
        <reference_text>Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49.</reference_text>
        <pubmed_id>7773620</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quazepam</name>
        <accession>HMDB15528</accession>
      </metabolite>
      <reference>
        <reference_text>Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy.  Epilepsia. 1986;27 Suppl 1:S3-13.</reference_text>
        <pubmed_id>3017690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quazepam</name>
        <accession>HMDB15528</accession>
      </metabolite>
      <reference>
        <reference_text>Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87.</reference_text>
        <pubmed_id>2892106</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cinolazepam</name>
        <accession>HMDB15533</accession>
      </metabolite>
      <reference>
        <reference_text>Walash MI, Belal F, Metwally ME, Hefnawy MM: A selective fluorimetric method for the determination of some 1,4-benzodiazepine drugs containing a hydroxyl group at C-3. J Pharm Biomed Anal. 1994 Nov;12(11):1417-23.</reference_text>
        <pubmed_id>7849137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
